BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet. 2002;39:608-610. [PMID: 12161606 DOI: 10.1136/jmg.39.8.608] [Cited by in Crossref: 118] [Cited by in F6Publishing: 101] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ, Jager A, Voogd AC, van Leeuwen FE, van 't Veer LJ. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. J Natl Cancer Inst 2017;109. [PMID: 28376189 DOI: 10.1093/jnci/djw329] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
2 Foulkes WD. BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective. Clin Genet 2014;85:1-4. [PMID: 24116874 DOI: 10.1111/cge.12291] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
3 Trusler O, Goodwin J, Laslett AL. BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. Biochim Biophys Acta Rev Cancer 2021;1875:188459. [PMID: 33129865 DOI: 10.1016/j.bbcan.2020.188459] [Reference Citation Analysis]
4 Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-44. [PMID: 17329194 DOI: 10.1016/S1470-2045(07)70074-8] [Cited by in Crossref: 569] [Cited by in F6Publishing: 277] [Article Influence: 40.6] [Reference Citation Analysis]
5 Takamizawa S, Ishiki H, Shimoi T, Shimizu M, Satomi E. Neoadjuvant Cisplatin in BRCA Carriers With HER2‐Negative Breast Cancer. JCO 2020;38:2699-700. [DOI: 10.1200/jco.20.00789] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet 2004;41:1-5. [PMID: 14729816 DOI: 10.1136/jmg.2003.013805] [Cited by in Crossref: 108] [Cited by in F6Publishing: 92] [Article Influence: 6.4] [Reference Citation Analysis]
7 Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The Role of BRCA1 in the Cellular Response to Chemotherapy. JNCI Journal of the National Cancer Institute 2004;96:1659-68. [DOI: 10.1093/jnci/djh312] [Reference Citation Analysis]
8 Di Leo A, Claudino WM, Pestrin M, Licitra S, Biganzoli L. Using specific cytotoxics with a targeted mind. Breast 2007;16 Suppl 2:S120-6. [PMID: 17720501 DOI: 10.1016/j.breast.2007.07.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
9 Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod SA. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14:R110. [PMID: 22817698 DOI: 10.1186/bcr3231] [Cited by in Crossref: 129] [Cited by in F6Publishing: 112] [Article Influence: 14.3] [Reference Citation Analysis]
10 AbdelHamid S, El-Mesallamy H, Aziz HA, Zekri AR. Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients. Biology (Basel) 2021;10:566. [PMID: 34206661 DOI: 10.3390/biology10070566] [Reference Citation Analysis]
11 Safra T. Hereditary ovarian cancer: biology, response to chemotherapy and prognosis. Womens Health (Lond) 2009;5:543-53. [PMID: 19702453 DOI: 10.2217/whe.09.40] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006;24:3799-808. [PMID: 16896009 DOI: 10.1200/JCO.2005.05.4171] [Cited by in Crossref: 210] [Cited by in F6Publishing: 101] [Article Influence: 14.0] [Reference Citation Analysis]
13 Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96:1659-1668. [PMID: 15547178 DOI: 10.1093/jnci/djh312] [Cited by in Crossref: 297] [Cited by in F6Publishing: 248] [Article Influence: 17.5] [Reference Citation Analysis]
14 Warner E, Trudeau M, Holloway C, Holloway C. Sensitivity of BRCA-1-Related Breast Cancer to Neoadjuvant Chemotherapy: Practical Implications. Breast Journal 2003;9:507-8. [DOI: 10.1046/j.1524-4741.2003.09624.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
15 Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Twenty-one-gene recurrence score assay in BRCA -associated versus sporadic breast cancers: Differences based on germline mutation status: Oncotype DX in BRCA Mutation Carriers. Cancer 2016;122:1178-84. [DOI: 10.1002/cncr.29903] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
16 Cortesi L, Masini C, Cirilli C, Medici V, Marchi I, Cavazzini G, Pasini G, Turchetti D, Federico M. Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer 2010;10:90. [PMID: 20219108 DOI: 10.1186/1471-2407-10-90] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
17 Kriege M, Seynaeve C, Meijers-heijboer H, Collee JM, Menke-pluymers MBE, Bartels CCM, Tilanus-linthorst MMA, van den Ouweland A, van Geel B, Brekelmans CTM, Klijn JGM. Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients. Breast Cancer Res Treat 2008;111:303-11. [DOI: 10.1007/s10549-007-9781-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
18 Imyanitov EN. Breast cancer therapy for BRCA1 carriers: moving towards platinum standard? Hered Cancer Clin Pract 2009;7:8. [PMID: 19379506 DOI: 10.1186/1897-4287-7-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
19 Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010;123:189-96. [PMID: 20582464 DOI: 10.1007/s10549-010-0983-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
20 Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. Cancer Sci 2018;109:166-73. [PMID: 29047188 DOI: 10.1111/cas.13426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep 2020;10:7073. [PMID: 32341426 DOI: 10.1038/s41598-020-63759-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
22 Gossage L, Madhusudan S. Cancer Pharmacogenomics: Role of DNA Repair Genetic Polymorphisms in Individualizing Cancer Therapy. Mol Diag Ther 2007;11:361-80. [DOI: 10.1007/bf03256260] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Goffin JR, Straume O, Chappuis PO, Brunet JS, Bégin LR, Hamel N, Wong N, Akslen LA, Foulkes WD. Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer 2003;89:1031-4. [PMID: 12966421 DOI: 10.1038/sj.bjc.6601195] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
24 Margeli M, Cirauqui B, Castella E, Tapia G, Costa C, Gimenez-Capitan A, Barnadas A, Sanchez Ronco M, Benlloch S, Taron M, Rosell R. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One 2010;5:e9499. [PMID: 20209131 DOI: 10.1371/journal.pone.0009499] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
25 Plakhins G, Irmejs A, Gardovskis A, Subatniece S, Liepniece-karele I, Purkalne G, Teibe U, Trofimovics G, Miklasevics E, Gardovskis J. Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients. Familial Cancer 2013;12:683-9. [DOI: 10.1007/s10689-013-9646-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
26 Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest 2010;28:172-80. [PMID: 19968494 DOI: 10.3109/07357900903095722] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
27 Stecklein SR, Jensen RA. Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. Transl Res 2012;160:178-97. [PMID: 22683426 DOI: 10.1016/j.trsl.2012.01.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
28 Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Törngren T, Diep A, Xue S, Bertelsen L, Liang X, Reiner AS, Capanu M, Malone KE; WECARE Collaborative Study Group. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 2010;123:491-8. [PMID: 20135344 DOI: 10.1007/s10549-010-0769-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
29 Huszno J, Budryk M, Kołosza Z, Nowara E. The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology 2013;85:278-82. [PMID: 24217135 DOI: 10.1159/000354834] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
30 Ponnusamy L, Mahalingaiah PKS, Singh KP. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells. European Journal of Pharmaceutical Sciences 2017;104:424-33. [DOI: 10.1016/j.ejps.2017.04.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
31 Vasconcelos de Matos L, Fernandes L, Louro P, Plácido A, Barros M, Vaz F. Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer. Curr Oncol 2021;28:485-90. [PMID: 33466630 DOI: 10.3390/curroncol28010050] [Reference Citation Analysis]
32 Murray M, Mullan P, Harkin D. Role played by BRCA1 in transcriptional regulation in response to therapy. Biochemical Society Transactions 2007;35:1342-6. [DOI: 10.1042/bst0351342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
33 Burness ML, Obeid EI, Olopade OI. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer 2015;15:e155-8. [PMID: 25445425 DOI: 10.1016/j.clbc.2014.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
34 Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 2007;20:474-81. [PMID: 17334350 DOI: 10.1038/modpathol.3800760] [Cited by in Crossref: 155] [Cited by in F6Publishing: 153] [Article Influence: 11.1] [Reference Citation Analysis]
35 James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP. BRCA1 , a Potential Predictive Biomarker in the Treatment of Breast Cancer. The Oncologist 2007;12:142-50. [DOI: 10.1634/theoncologist.12-2-142] [Cited by in Crossref: 102] [Cited by in F6Publishing: 81] [Article Influence: 7.3] [Reference Citation Analysis]
36 Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011;29:3739-46. [PMID: 21900106 DOI: 10.1200/JCO.2011.35.2682] [Cited by in Crossref: 113] [Cited by in F6Publishing: 49] [Article Influence: 11.3] [Reference Citation Analysis]
37 Harte MT, Gorski JJ, Savage KI, Purcell JW, Barros EM, Burn PM, McFarlane C, Mullan PB, Kennedy RD, Perkins ND, Harkin DP. NF-κB is a critical mediator of BRCA1-induced chemoresistance. Oncogene 2014;33:713-23. [PMID: 23435429 DOI: 10.1038/onc.2013.10] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
38 Fourquet A, Stoppa-lyonnet D, Kirova YM, Sigal-zafrani B, Asselain B. Familial Breast Cancer: Clinical Response to Induction Chemotherapy or Radiotherapy Related to BRCA1/2 Mutations Status. American Journal of Clinical Oncology 2009;32:127-31. [DOI: 10.1097/coc.0b013e31817f9e1c] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
39 Oakman C, Pestrin M, Cantisani E, Licitra S, Destefanis M, Biganzoli L, Di Leo A. Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more? The Breast 2009;18:S18-24. [DOI: 10.1016/s0960-9776(09)70267-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006;5:135-42. [PMID: 16736282 DOI: 10.1007/s10689-005-2832-5] [Cited by in Crossref: 100] [Cited by in F6Publishing: 80] [Article Influence: 6.7] [Reference Citation Analysis]
41 Lobitz S, Velleuer E. Guido Fanconi (1892-1979): a jack of all trades. Nat Rev Cancer. 2006;6:893-898. [PMID: 17036037 DOI: 10.1038/nrc2009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
42 Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 2010;7:708-17. [DOI: 10.1038/nrclinonc.2010.175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
43 Kawachi K, Sasaki T, Murakami A, Ishikawa T, Kito A, Ota I, Shimizu D, Nozawa A, Nagashima Y, Machinami R, Aoki I. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy. Pathol Res Pract 2010;206:156-62. [PMID: 20089371 DOI: 10.1016/j.prp.2009.10.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
44 El Hage Chehade H, Wazir U, Mokbel K, Kasem A, Mokbel K. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature. Am J Surg 2018;215:171-8. [PMID: 28622841 DOI: 10.1016/j.amjsurg.2017.05.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
45 Euhus DM, Robinson L. Genetic Predisposition Syndromes and Their Management. Surgical Clinics of North America 2013;93:341-62. [DOI: 10.1016/j.suc.2013.01.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
46 Muggia F, Safra T, Dubeau L. BRCA genes: lessons learned from experimental and clinical cancer. Ann Oncol 2011;22 Suppl 1:i7-10. [PMID: 21285156 DOI: 10.1093/annonc/mdq659] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
47 Moule R, Sohaib A, Eeles R. Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation. Clin Oncol (R Coll Radiol) 2009;21:444-7. [PMID: 19574032 DOI: 10.1016/j.clon.2009.04.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
48 Scata KA, El-Deiry WS. p53, BRCA1 and breast Cancer chemoresistance. Adv Exp Med Biol 2007;608:70-86. [PMID: 17993233 DOI: 10.1007/978-0-387-74039-3_5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
49 Laroche-Clary A, Chaire V, Le Morvan V, Neuville A, Bertucci F, Salas S, Sanfilippo R, Pourquier P, Italiano A. BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. Br J Cancer 2015;112:688-92. [PMID: 25602962 DOI: 10.1038/bjc.2014.624] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
50 Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009;20:1913-1927. [PMID: 19901010 DOI: 10.1093/annonc/mdp492] [Cited by in Crossref: 357] [Cited by in F6Publishing: 331] [Article Influence: 29.8] [Reference Citation Analysis]
51 Kwon WS, Rha SY, Jeung HC, Kim TS, Chung HC. Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. Biochem Pharmacol 2017;138:163-73. [PMID: 28431939 DOI: 10.1016/j.bcp.2017.04.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
52 Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. The Breast 2010;19:312-21. [DOI: 10.1016/j.breast.2010.03.026] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 11.5] [Reference Citation Analysis]
53 Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 2005;91:179-86. [PMID: 15868446 DOI: 10.1007/s10549-004-7603-8] [Cited by in Crossref: 120] [Cited by in F6Publishing: 115] [Article Influence: 7.5] [Reference Citation Analysis]
54 Francken AB, Schouten PC, Bleiker EM, Linn SC, Rutgers EJ. Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies. Breast 2013;22:561-8. [PMID: 23972475 DOI: 10.1016/j.breast.2013.07.045] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
55 Brekelmans C, Seynaeve C, Menke-pluymers M, Brüggenwirth H, Tilanus-linthorst M, Bartels C, Kriege M, van Geel A, Crepin C, Blom J, Meijers-heijboer H, Klijn J. Survival and prognostic factors in BRCA1-associated breast cancer. Annals of Oncology 2006;17:391-400. [DOI: 10.1093/annonc/mdj095] [Cited by in Crossref: 102] [Cited by in F6Publishing: 84] [Article Influence: 6.8] [Reference Citation Analysis]
56 Nahleh Z. Neoadjuvant chemotherapy for “Triple Negative” breast cancer: a review of current practice and future outlook. Med Oncol 2010;27:531-9. [DOI: 10.1007/s12032-009-9244-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
57 Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod SA, Lubinski J; Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008;108:289-96. [PMID: 17492376 DOI: 10.1007/s10549-007-9600-1] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 7.1] [Reference Citation Analysis]
58 Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 2012;118:899-907. [PMID: 21761396 DOI: 10.1002/cncr.26351] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
59 Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 105] [Article Influence: 16.7] [Reference Citation Analysis]
60 Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-9. [PMID: 20008645 DOI: 10.1200/JCO.2008.20.7019] [Cited by in Crossref: 365] [Cited by in F6Publishing: 174] [Article Influence: 30.4] [Reference Citation Analysis]
61 Narod SA, Offit K. Prevention and Management of Hereditary Breast Cancer. JCO 2005;23:1656-63. [DOI: 10.1200/jco.2005.10.035] [Cited by in Crossref: 119] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
62 Savage K, Harkin DP. BRCA1 and BRCA2: Role in the DNA Damage Response, Cancer Formation and Treatment. In: Khanna KK, Shiloh Y, editors. The DNA Damage Response: Implications on Cancer Formation and Treatment. Dordrecht: Springer Netherlands; 2009. pp. 415-43. [DOI: 10.1007/978-90-481-2561-6_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Hubert A, Mali B, Hamburger T, Rottenberg Y, Uziely B, Peretz T, Kadouri L. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Familial Cancer 2009;8:173-7. [DOI: 10.1007/s10689-008-9223-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
64 Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist 2013;18:909-16. [PMID: 23881989 DOI: 10.1634/theoncologist.2013-0039] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
65 Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa SD, Roessner A, Kalinski T, Bischoff J. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC. Breast Cancer Res Treat 2013;141:205-12. [PMID: 24026861 DOI: 10.1007/s10549-013-2693-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
66 Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet J, Hamel N, Paradis A, Boyd J, Foulkes WD. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-Year follow-up data. Cancer 2003;97:527-36. [DOI: 10.1002/cncr.11080] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 4.3] [Reference Citation Analysis]
67 Voduc D, Nielsen TO. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. Clin Breast Cancer 2008;8 Suppl 4:S171-8. [PMID: 19158038 DOI: 10.3816/CBC.2008.s.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
68 Price M, Monteiro AN. Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol 2010;80:647-53. [PMID: 20510205 DOI: 10.1016/j.bcp.2010.05.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
69 Liu Y, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer. BMC Cancer 2015;15:194. [PMID: 25884806 DOI: 10.1186/s12885-015-1203-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
70 Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568-2581. [PMID: 18487574 DOI: 10.1200/jco.2007.13.1748] [Cited by in Crossref: 587] [Cited by in F6Publishing: 289] [Article Influence: 45.2] [Reference Citation Analysis]
71 Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol. 2008;26:3259-3267. [PMID: 18591560 DOI: 10.1200/jco.2007.11.3902] [Cited by in Crossref: 48] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
72 Atipairin A, Canyuk B, Ratanaphan A. Cisplatin Affects the Conformation of Apo Form, not Holo Form, of BRCA1 RING Finger Domain and Confers Thermal Stability. Chemistry & Biodiversity 2010;7:1949-67. [DOI: 10.1002/cbdv.200900308] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
73 Rubinstein WS. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Familial Cancer 2008;7:83-9. [DOI: 10.1007/s10689-007-9147-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
74 Italiano A, Laurand A, Laroche A, Casali P, Sanfilippo R, Le Cesne A, Judson I, Blay JY, Ray-Coquard I, Bui B, Coindre JM, Nieto A, Tercero JC, Jimeno J, Robert J, Pourquier P. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer 2011;117:3445-56. [PMID: 21287534 DOI: 10.1002/cncr.25925] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
75 Hámori L, Kudlik G, Szebényi K, Kucsma N, Szeder B, Póti Á, Uher F, Várady G, Szüts D, Tóvári J, Füredi A, Szakács G. Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line. Int J Mol Sci 2020;21:E1185. [PMID: 32053991 DOI: 10.3390/ijms21041185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009;11:205. [PMID: 19435470 DOI: 10.1186/bcr2238] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
77 Yamamoto Y, Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010;15:341-51. [PMID: 20632057 DOI: 10.1007/s10147-010-0106-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
78 Rodríguez-pinilla SM, Rodríguez-gil Y, Moreno-bueno G, Sarrió D, Martín-guijarro MDC, Hernandez L, Palacios J. Sporadic Invasive Breast Carcinomas With Medullary Features Display a Basal-like Phenotype: An Immunohistochemical and Gene Amplification Study. American Journal of Surgical Pathology 2007;31:501-8. [DOI: 10.1097/01.pas.0000213427.84245.92] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
79 Bayraktar S, Glück S. Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat 2012;135:355-66. [PMID: 22791366 DOI: 10.1007/s10549-012-2158-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
80 Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, Eisen A, Foulkes WD, Rosen B, Vesprini D, Sun P, Narod SA. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2011;127:287-96. [PMID: 21221768 DOI: 10.1007/s10549-010-1336-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
81 De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V, De Placido S. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treatment Reviews 2010;36:S80-6. [DOI: 10.1016/s0305-7372(10)70025-6] [Cited by in Crossref: 100] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
82 Conroy M, Borad MJ, Bryce AH. Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. Cureus 2017;9:e1517. [PMID: 28959512 DOI: 10.7759/cureus.1517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Dębska-Szmich S, Krakowska M, Czernek U, Habib-Lisik M, Zięba A, Potemski P. The role of preoperative systemic treatment in patients with breast cancer. Contemp Oncol (Pozn) 2016;20:93-101. [PMID: 27358586 DOI: 10.5114/wo.2016.60067] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
84 Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9:5. [PMID: 21819606 DOI: 10.1186/1897-4287-9-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
85 Euhus D, Robinson L. Genetic Counseling and Genetic Testing in the Preoperative Evaluation of Breast Cancer Patients. Curr Breast Cancer Rep 2012;4:102-9. [DOI: 10.1007/s12609-012-0071-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 El-tamer M, Russo D, Troxel A, Bernardino LP, Mazziotta R, Estabrook A, Ditkoff B, Schnabel F, Mansukhani M. Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers. Ann Surg Oncol 2004;11:157-64. [DOI: 10.1245/aso.2004.05.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
87 Carey LA. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. J Clin Oncol 2010;28:361-3. [PMID: 20008634 DOI: 10.1200/JCO.2009.24.0838] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
88 Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med 2017;23:517-25. [PMID: 28288110 DOI: 10.1038/nm.4292] [Cited by in Crossref: 365] [Cited by in F6Publishing: 276] [Article Influence: 91.3] [Reference Citation Analysis]
89 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
90 Keet AWW, Al‐rafae M, Chappuis PO, Brunet J, Ghadirian P, Foulkes WD. Long‐term outcome after neo‐adjuvant chemotherapy for breast cancer in BRCA1/2 carriers. Int J Cancer 2009;125:2236-8. [DOI: 10.1002/ijc.24596] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
91 Robson ME. Treatment of hereditary breast cancer. Semin Oncol 2007;34:384-91. [PMID: 17920892 DOI: 10.1053/j.seminoncol.2007.07.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
92 Brunet J. Hereditary breast cancer and genetic counseling in young women. Breast Cancer Res Treat 2010;123 Suppl 1:7-9. [PMID: 20711663 DOI: 10.1007/s10549-010-1050-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
93 Grandal B, Evrevin C, Laas E, Jardin I, Rozette S, Laot L, Dumas E, Coussy F, Pierga JY, Brain E, Saule C, Stoppa-Lyonnet D, Frank S, Sénéchal C, Lae M, De Croze D, Bataillon G, Guerin J, Reyal F, Hamy AS. Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers (Basel) 2020;12:E3681. [PMID: 33302444 DOI: 10.3390/cancers12123681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
94 Oakman C, Moretti E, Galardi F, Biagioni C, Santarpia L, Biganzoli L, Di Leo A. Adjuvant systemic treatment for individual patients with triple negative breast cancer. The Breast 2011;20:S135-41. [DOI: 10.1016/s0960-9776(11)70311-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
95 Kriege M, Seynaeve C, Meijers-heijboer H, Collee JM, Menke-pluymers MB, Bartels CC, Tilanus-linthorst MM, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG. Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JCO 2009;27:3764-71. [DOI: 10.1200/jco.2008.19.9067] [Cited by in Crossref: 75] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
96 Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-76. [PMID: 15343273 DOI: 10.1038/nrc1431] [Cited by in Crossref: 581] [Cited by in F6Publishing: 498] [Article Influence: 34.2] [Reference Citation Analysis]
97 Raphael J, Mazouni C, Caron O, Ferchiou M, Delaloge S. Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy? Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0850-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
98 Vargas AC, Reis-Filho JS, Lakhani SR. Phenotype-genotype correlation in familial breast cancer. J Mammary Gland Biol Neoplasia 2011;16:27-40. [PMID: 21400086 DOI: 10.1007/s10911-011-9204-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
99 Nicolas E, Bertucci F, Sabatier R, Gonçalves A. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? Cancers (Basel) 2018;10:E506. [PMID: 30544963 DOI: 10.3390/cancers10120506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
100 Mullan PB, Gorski JJ, Harkin DP. BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment? Biochim Biophys Acta 2006;1766:205-16. [PMID: 16919882 DOI: 10.1016/j.bbcan.2006.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.2] [Reference Citation Analysis]
101 Euhus DM. New insights into the prevention and treatment of familial breast cancer. J Surg Oncol 2011;103:294-8. [PMID: 21337561 DOI: 10.1002/jso.21664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]